RxDoctor Payments Data

Donalda Isidore

Family · Bridgeport, CTNPI 1407317670

Payments from drug & device makers

$3,498in general payments, 2019–2025

Across 71 payments — averaging $49.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$875
  • Otsuka America Pharmaceutical, Inc.$554
  • Neurocrine Biosciences, Inc.$494
  • Lundbeck LLC$236
  • AbbVie$188
  • plus $109 from 1 others

What the payments were for

  • Food & beverage$3,498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,498 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$182,272
Medicare patients
293
Services billed
2,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole39$109,053
IngrezzaValbenazine Tosylate15$93,717
Invega SustennaPaliperidone Palmitate11$37,606
AristadaAripiprazole Lauroxil11$34,763
Risperidone ErRisperidone Microspheres13$28,382
Clozapine61$4,365
EliquisApixaban14$4,285
Paliperidone ErPaliperidone34$3,850
Trazodone Hcl275$3,293
Quetiapine Fumarate142$2,978
Divalproex Sodium45$2,871
Sertraline Hcl210$1,998
Risperidone134$1,654
Olanzapine65$1,565
Prazosin Hcl27$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$554$109,05339 claims
Neurocrine Biosciences, Inc.Ingrezza$494$93,71715 claims
Alkermes, Inc.Aristada$875$34,76311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →